Thus, due to the unusual evolution of the BC, BRAF gene mutations and PD-L1 expression were retrospectively evaluated, using quantitative real-time polymerase chain reaction (qPCR), respectively immunohistochemistry (IHC), on post-TURBT tissue specimens, from before (pre-) and after (post-) complete spontaneous bladder tumor necrosis under Nivolumab. This evidence concerns the gene BRAF and urinary bladder neoplasm.